Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat

Regeneron just reported a second-quarter earnings and revenue win

Fernanda Horner

Digital Content Manager

Aug 3, 2023 at 10:40 AM

REGN

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations. The company attributed the results to a 33% sales surge for its eczema drug Dupixent, and noted it expects the Food and Drug Administration (FDA) to approve a higher-dose version of eye disease drug Eylea in the third quarter.

Last seen up 5% at $768.51 at last check, the stock earlier moved above its 80-day moving average for the first time since late June. Overhead pressure at the $780 remains firmly in place, but over the past 12 months Regeneron Pharmaceuticals stock added 26.6%.

Drilling down to today's options activity, 1,219 calls have been exchanged -- five times the intraday average volume -- compared to just 433 puts. The most popular is the weekly 8/25 780-strike call, followed by the weekly 8/11 780-stike call, with new positions being opened at both.

Follow @Schaeffers

The $25k Day Trading Barrier is Gone. It's Time to Put Your Capital to Work.

For years, the PDT rule put a major roadblock in front of active traders. The barrier is no longer standing in the way.

But having more freedom doesn't mean every trade is worth taking.

With Dynamite Day Trading Signals, you'll receive up to 2 options trade alerts per week, each targeting 50%+ gains in a single session.

NO holding positions overnight.

NO waiting weeks for a trade to develop.

Just focused options trades designed to capitalize on opportunities as they emerge.

👉 Get Access to Dynamite Day Trading Signals